Matches in Wikidata for { <http://www.wikidata.org/entity/Q62025582> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q62025582 description "clinical trial" @default.
- Q62025582 description "ensayo clínico" @default.
- Q62025582 description "ensayu clínicu" @default.
- Q62025582 description "klinisch onderzoek" @default.
- Q62025582 description "клінічне випробування" @default.
- Q62025582 description "临床试验" @default.
- Q62025582 name "Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)" @default.
- Q62025582 type Item @default.
- Q62025582 label "Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)" @default.
- Q62025582 prefLabel "Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)" @default.
- Q62025582 P1050 Q62025582-9689AD44-AD45-4C71-89F4-955188E1AD22 @default.
- Q62025582 P1050 Q62025582-C10B6B19-D697-4C1C-9E3F-F7D47DEC216E @default.
- Q62025582 P1132 Q62025582-6486F85D-399B-4113-94E2-34C22317F9FD @default.
- Q62025582 P1476 Q62025582-58A5CBDC-C092-4C35-8559-A239BA7C62FF @default.
- Q62025582 P17 Q62025582-EDDEC0D5-3BC4-4740-9539-2B764FFB517D @default.
- Q62025582 P1813 Q62025582-9DADFBC9-7AA8-405B-8307-0D4027F6A222 @default.
- Q62025582 P2899 Q62025582-BAFD9098-F5EF-403A-B6F7-FF29341F72A3 @default.
- Q62025582 P3098 Q62025582-6D6ADC6F-851B-4464-9D9F-A1D6F8B373EE @default.
- Q62025582 P31 Q62025582-D0F0C34A-0553-4306-B895-818222611247 @default.
- Q62025582 P4844 Q62025582-7B6075B1-528B-4D02-B224-F6827DAD05A2 @default.
- Q62025582 P580 Q62025582-723C832B-9A2C-4CFC-AE5E-EBDAD2B98B5B @default.
- Q62025582 P582 Q62025582-1CBD9A63-DDA7-443A-9192-646585214243 @default.
- Q62025582 P6099 Q62025582-C3A95163-5276-4A01-9999-BF8BFF5E99D0 @default.
- Q62025582 P6153 Q62025582-07CD7DEA-0F03-4ABD-BD2B-5FA39268E0C1 @default.
- Q62025582 P6153 Q62025582-1079B162-DC5D-4A0C-918F-D8569FDBDFBF @default.
- Q62025582 P6153 Q62025582-75DCE99B-A1ED-478F-960D-3A4D67062EFB @default.
- Q62025582 P6153 Q62025582-78FE381B-659D-4553-BDAE-E97E3B01243C @default.
- Q62025582 P6153 Q62025582-9949A664-7B78-4E17-AA12-81850A6E4216 @default.
- Q62025582 P6153 Q62025582-F81D6F71-67AF-400F-8891-967709AE9FB0 @default.
- Q62025582 P8005 Q62025582-FCFB5C10-6785-4B93-A234-37D84EF23C9A @default.
- Q62025582 P8363 Q62025582-AA37E824-C44D-4604-9B37-A0DE3B0CB378 @default.
- Q62025582 P859 Q62025582-D93E1A2A-8996-4118-A279-3A9ED7F3AC4B @default.
- Q62025582 P921 Q62025582-7DFA917D-C99F-4D61-8940-37458099334D @default.
- Q62025582 P1050 Q356033 @default.
- Q62025582 P1050 Q5038170 @default.
- Q62025582 P1132 "+126" @default.
- Q62025582 P1476 "An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)" @default.
- Q62025582 P17 Q145 @default.
- Q62025582 P1813 "DICE" @default.
- Q62025582 P2899 "+18" @default.
- Q62025582 P3098 "NCT03648489" @default.
- Q62025582 P31 Q30612 @default.
- Q62025582 P4844 Q423762 @default.
- Q62025582 P580 "2018-09-21T00:00:00Z" @default.
- Q62025582 P582 "2022-03-01T00:00:00Z" @default.
- Q62025582 P6099 Q42824440 @default.
- Q62025582 P6153 Q14956770 @default.
- Q62025582 P6153 Q170027 @default.
- Q62025582 P6153 Q5110676 @default.
- Q62025582 P6153 Q5118186 @default.
- Q62025582 P6153 Q7063709 @default.
- Q62025582 P6153 Q7569131 @default.
- Q62025582 P8005 Q76649708 @default.
- Q62025582 P8363 Q78089383 @default.
- Q62025582 P859 Q189022 @default.
- Q62025582 P921 Q54553364 @default.